Company news

Patrys Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Change of Auditor

November 11, 2026

Change in substantial holding

November 9, 2026

Change of Director's Interest Notice x2

November 9, 2026

Cleansing Notice

November 9, 2026

Application for quotation of securities - PAB

November 9, 2026

Letter to Shareholders - Annual General Meeting

October 29, 2026

Notice of Annual General Meeting/Proxy Form

October 29, 2026

Appendix 4C - Quarterly - 30 September 2026

October 28, 2026

Appendix 4C - Quarterly - 30 September 2026

October 28, 2026

RLS-2202 Phase 1a Trial Advances to Cohort 2

October 21, 2026

RLS-2202 Phase 1a Trial Advances to Cohort 2

October 21, 2026

Investor Presentation

October 12, 2026

Investor Webinar

October 5, 2026

Date of AGM and Closing Date for Director Nominations

October 5, 2026

Notification of cessation of securities - PAB

September 30, 2026

Patrys Completes Cohort 1 Dosing and Follow-Up

September 28, 2026

Appendix 4E Variance Report

September 28, 2026

Annual Report - 30 June 2025

September 28, 2026

Appendix 4G and Corporate Governance Statement

September 28, 2026

First Participants Dosed in RLS-2202 Phase 1A Clinical Trial

September 22, 2026

PAB Establishes Clinical Advisory Committee

September 16, 2026

Appendix 4E - Preliminary Final Report

August 31, 2026

Ethics Approval Secured for Phase 1A Clinical Trial

August 27, 2026

Investor Presentation - TechKnow Invest Roadshow

July 26, 2026

Appendix 4C - Quarterly - 30 June 2026

July 21, 2026

Patrys Secures 50% Revenue Share in IP Commercialisation

July 12, 2026

Patrys advances RLS-2202 toward Phase 1 Clinical Trial

May 19, 2026

Appendix 4C - Quarterly - 31 March 2026

April 29, 2026

$3.2 million Placement to Advance Clinical Trials

April 19, 2026

Investor Presentation - Broker Meets Biotech

March 30, 2026

RLS-2201 Manufacturing and Regulatory Pathway Initiated

March 10, 2026

Appendix 4D - Half Year Accounts - 31 December 2025

February 26, 2026

Appointment of Chief Executive Officer

February 11, 2026

Appendix 4C - Quarterly - 31 December 2025

January 29, 2026

Investor Presentation

January 27, 2026

Completion of Acquisition and Board Appointments

January 27, 2026

Pipeline Expanded with Proprietary Injectable Antipsychotic

November 25, 2025

Trading Halt

November 23, 2025

Appendix 4C - Quarterly - 30 September 2025

October 29, 2025

Patrys Receives R&D Tax Incentive Refund

October 29, 2025

Notice of Annual General Meeting/Proxy Form

September 7, 2025

Appendix 4E - Preliminary Final Report

August 29, 2025

Appendix 4C - Quarterly - 30 June 2025

July 29, 2025

Entitlement Offer Prospectus

July 23, 2025

Non-Renounceable Entitlement Offer

July 23, 2025

Deed of Release entered into with CEO

June 16, 2025

Successful Placement and Board Changes

June 10, 2025

Reinstatement to Official Quotation

June 10, 2025

Suspension from Quotation

June 3, 2025

Appendix 4C - Quarterly - 31 March 2025

April 30, 2025

Older news releases →

Decks

The 5 newest of 46 decks. Every deck is listed under its year.